Keywords
kidney transplantation
poliomavirus infection
immunosuppressive therapy
How to Cite
Abstract
Immunosuppressive therapy is considered to be one of the main risk factors for replication of BK and JC polyomaviruses after kidney transplantation. The effective treatment regimens for dysfunction of the kidney transplantation have been studied in patients with chronic kidney disease V stage with polyomavirus infection. 97 patients with transplanted kidneys during the first year after transplantation were examined. The frequency of detection of BK and JC viruria, JC viruria and viremia was 5 (16.13 %). The frequency of BK viruria was 10 (32.26 %), isolated JC viruria – 2 (6.45 %) and ВК viruria – 1 (3.23 %), simultaneous detection of the JC і ВК viruses was observed in 3 (9.68 %). There are 12 patients with persistant ВК viruria and viremia who need to change immunosuppressive therapy. The median time to detection of persistant BK-viruria and viremia after transplantation in patients with tacrolimus was (12.29±7.16) weeks, in patients with cyclosporine was (12.29±7.16) weeks. The period for elimination of polyomavirus in patients with cyclosporine and mycophenolates included (13.00±5.13) weeks, and in patients with cyclosporine and everolimus included (7.00±2.58) weeks. This investigation revealed different patterns of the treatment of kidney transplant dysfunction caused by BK-polyomavirus infection. The first step in the treatment of BKV infection is reduction in immunosuppression. In this study, we did conversion from tacrolimus to cyclosporine or conversion from mycophenolates to everolimus with restriction of cyclosporine doses. The last strategy showed better results because period for elimination of polyomavirus was shorter.
References
Harambat J., Bonthuis M., van Stralen K.J., Ariceta G., Battelino N., Bjerre A. et al. (2014). Adult height in patients with advanced CKD requiring renal replacement therapy during childhood. Clin. J. Am. Soc. Nephrol., vol. 9 (1), pp. 92–99, DOI 10.2215/CJN.00890113.
Anzivino E., Bellizzi A., Mitterhofer A.P., Tinti F., Barile M., Colosimo M.T. et al. (2011). Early monitoring of the human polyomavirus BK replication and sequencing analysis in a cohort of adult kidney transplant patients treated with basiliximab. Virol. J., vol. 8, pp. 407.
Egli A., Infanti L., Dumoulin A., Buser A., Samaridis J., Stebler C. et al. (2009). Prevalence of polyomavirus BK and JC infection and replication in 400 healthy blood donors. J. Infect. Dis., vol. 199, pp. 837–846.
Comoli P., Cioni M., Basso S., Gagliardone C., Potenza L., Verrina E. et al. (2013). Immunity to polyomavirus BK infection: immune monitoring to regulate the balance between risk of BKV nephropathy and induction of alloimmunity. Clin. Dev. Immunol., vol. 2013, pp. 25–27.
Sawinski D., Goral S. (2015). BK virus infection: an update on diagnosis and treatment. Nephrol. Dial. Transplant., vol. 30 (2), 209–217.
Beimler J., Sommerer C., Zeier M. (2007). The influence of immunosuppression on the development of BK virus nephropathy – does it matter? Nephrol. Dial. Transplant., vol. 22 (8), pp. 66–71.
Bohl D.L., Brennan D.C. (2007). BK virus nephropathy and kidney transplantation. Clin. J. Am. Soc. Nephrol., vol. 2, suppl. 1, pp. S36–S46.
Drachenberg C.B., Hirsch H.H., Papadimitriou J.C., Gosert R., Wali R.K., Munivenkatappa R. et al. (2007). Polyomavirus BK versus JC replication and nephropathy in renal transplant recipients: a prospective evaluation. Transplantation, vol. 84, pp. 323–330.
Garces J.C. (2010). BK virus-associated nephropathy in kidney transplant recipients. Ochsner J., vol. 10, pp. 245–249.
Ranjan R., Rani A., Brennan D.C., Finn P.W., Perkins D.L. (2017). Complete genome sequence of BK polyomavirus subtype Ib-1 detected in a kidney transplant patient with BK viremia using shotgun sequencing. Genome Announc., vol. 5 (6), pii e01474–16.
Hirsch H.H., Vincenti F., Friman S., Tuncer M., Citterio F., Wiecek A. et al. (2013). Polyomavirus BK replication in de novo kidney transplant patients receiving tacrolimus or cyclosporine: a prospective, randomized, multicenter study. Am. J. Transplant., vol. 13, pp. 136–145.
Shah K.V. (2000). Human polyomavirus BKV and renal disease. Nephrol. Dial. Transplant., vol. 15, pp. 754–755.
Randhawa P., Brennan D.C. (2006). BK virus infection in transplant recipients: an overview and update. Am. J. of Transplant., vol. 6 (9), pp. 2000–2005.
Knowles W.A., Pipkin P., Andrews N., Vyse A., Minor P., Brown D.W., Miller E. (2003). Population-based study of antibody to the human polyomaviruses BKV and JCV and the simian polyomavirus SV40. J. Med. Virol., vol. 71 (1), pp. 115–123.